ArticleAnimal models and experimental medicine2025
Cistanche tubulosa improves peripheral neuropathy in MPTP-induced PD mice based on regulation of m6A methylation.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Tubuloside B ameliorates blood-brain barrier disruption and cognitive deficits after cerebral ischemia by inhibiting TRIC protein ubiquitination and degradation.Journal of neuroinflammation · 2025Article
- Cistanche tubulosa improves peripheral neuropathy in MPTP-induced PD mice based on regulation of m6A methylation.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to discover whether Cistanche tubulosa affects the AKT/CASP3 pathway by regulating m6A methylation, to exert a protective effect against peripheral nerve injury in a Parkinson's Disease (PD) mouse model.
methodsIn this study, network pharmacology analysis and the molecular docking virtual screening technique was used to filter Acteoside (Act), a potential neuroprotective agent of active components in Cistanche tubulosa. A PD-related peripheral neuropathy mouse model was established by MPTP induction, followed by 21 days treatment of oral Act (25, 50, and 100 mg kg
resultsThe results showed that peripheral neuropathy occurring with PD in the mouse model, which could be verified by behavioral tests and pathological histological changes. In addition to the previously established protective effect of Act on dopaminergic neurons in substantia nigra (SN), extensive follow-up studies demonstrated that Act effectively induced m6A methylation, which could further regulate the AKT/CASP3 pathway to play a therapeutic role. In this study, medium and high doses of Act played more obvious therapeutic roles.
conclusionThese findings suggest that Act may regulate the severity of peripheral nerve injury under the activation of the AKT/CASP3 signaling pathway by balancing the methylation level of m6A. These results provide a theoretical basis and experimental evidence for further research on the protective effect of Cistanche tubulosa on both the central and peripheral nerves in the treatment of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.